BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210209
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T145950
CREATED:20201022T101624Z
LAST-MODIFIED:20201022T104507Z
UID:27586-1612828800-1613087999@www.pharmajournalist.com
SUMMARY:Gene Therapy Medical Affairs
DESCRIPTION:The inaugural Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role that Medical Affairs plays in delivering gene therapies to patients. \nIndustry pioneers from leading pharma and biotech companies at various stages of development and commercialization including Novartis Gene Therapy\, Orchard Therapeutics & Bluebird Bio will share how to engage effectively with internal clinical and commercial teams as well as external HCPs\, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex\, high priced gene therapy products and ultimately work to remove both barriers that exist for access to gene therapies. \n \nJoin this definitive\, niche conference to delve into the unique Medical Affairs challenges encountered when working with gene therapies\, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch scrutiny\, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before. \nThis virtual event is set to be a highly interactive and engaging meeting. We fully understand (and quite frankly agree) that a presentation-heavy conference just isn’t up to scratch! As such we have created a new format for this meeting which maximises opportunities for engagement\, discussion\, and Q&A’s in order for you to get the best value from this meeting. \nTo know more about Gene Therapy Medical Affairs please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-medical-affairs/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T145950
CREATED:20201001T101330Z
LAST-MODIFIED:20201019T092845Z
UID:27319-1612915200-1613087999@www.pharmajournalist.com
SUMMARY:RNA Therapeutics 2021
DESCRIPTION:Innovations in technologies and applications of RNA-based medicine \nRNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines\, and treatment of genetic\, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025\, growing at a CAGR of 7.5%. Furthermore\, the recent advent of CRISPR\, an RNA-guided gene-editing technology\, as well as new strides in the delivery of messenger RNA transcribed in vitro\, have triggered a major expansion of the RNA-therapeutics field. \nThe 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies\, oligonucleotide delivery\, therapeutic applications and future trends and innovations. \n \nJoin us in February 2021\, as SMi’s 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry\, upcoming regulatory updates and industry implications. \nBENEFITS OF ATTENDING:  \n\nExplore in industry insights into how mRNA is being used to combat COVID-19\nEngage in case studies exploring the growing therapeutic potential of RNA for rare diseases\nDelve into future trends in AI application for optimal RNA therapeutics\nHear regulatory outlooks of the RNA landscape\, clinical trials and looking ahead\n\nView the full agenda and speaker line-up online: www.therapeutics-rna.com/pjwl \nFocus day on RNA Interference – 12TH February 2021\n\nAs the industry of RNA therapeutics advances this year’s focus day will explore the growing potential of RNA interference. The focus day will present sessions that explore the evolving approaches to RNAi including: antifibrotic microRNA-based therapeutics for the treatment of Alport syndrome\, self-deliverable RNAi and an exploration into how siRNA can be modified for self-delivery\, and targeted delivery of nucleic acid therapeutics. Furthermore\, this year’s focus day will be highlighting the emerging trends and future outlook of RNAi in the Pharmaceutical industry. \nEARLY-BIRD RATES:  \n\nBOOK BY 30TH OCTOBER AND SAVE £400\nBOOK BY 30TH NOVEMBER AND SAVE £200\nBOOK BY 11TH DECEMBER AND SAVE £100\n\nRegistrations can be made on the event website at: www.therapeutics-rna.com/pjwl \nChairs for 2021: \nHeinrich Haas\, VP RNA Formulation and Drug Delivery\, BioNTech \nFocus Day Chair for 2021: Shalini Andersson\, Chief Scientist New Therapeutic Modalities & Head of Oligonucleotide Discovery\, AstraZeneca \nFeatured speakers:  \n\nDong Yu\, Fellow\, Senior Director\, and Head\, GSK Vaccines\nMaria Luisa Pineda\, CEO and Co-Founder\, Envisagenics\nKirsty Wydenbach\, Deputy Unit Manager/Senior Medical Assessor\, MHRA\nDong Ki Lee\, CEO\, OliX\nJennifer Pluim\, Vice President Medical Affairs\, ProQR\nArpan Desai\, Team Leader\, Advanced Drug Delivery\, Pharmaceutical Sciences\, AstraZeneca\nRuchi Shah\, Senior Research Engineer\, New Therapeutics Modalities\, Eli Lilly and Company\nMichael Mulqueen\, Vice President Business Development\, eTheRNA immunotherapies\nTroels Koch\, Founder & CEO\, Aqiventa\n\nWho should attend: \n\nResearch & Development Directors/Managers/Scientists\nHeads of Clinical Development\nHeads of Pre-Clinical Development\nHead of RNA Biology\nHead of RNA Formulation and Drug Delivery\nHead of Pre-clinical R&D\nHead of New Modalities\nHead of Discovery\nSenior Scientists\nChief Scientific Officers\nChief Medical Officers\n\nAdditional Contact Info: \nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nFollow us:  @SMiPharm #SMirna
URL:https://www.pharmajournalist.com/event/rna-therapeutics-2021/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210212
DTSTAMP:20260515T145950
CREATED:20201012T114728Z
LAST-MODIFIED:20201012T114728Z
UID:27476-1612915200-1613087999@www.pharmajournalist.com
SUMMARY:SMi’s 5th Annual 3D Cell Culture Conference
DESCRIPTION:Sponsored by: Celvivo \nChaired by: Stefan Przyborski\, Professor of Cell Technology\, Durham University \nDeveloping Complex Physiologically Relevant Cell Models in Vitro \n3D Cell Culture is gaining momentum in the pharmaceutical industry\, with the global 3D Cell Culture market predicted to surpass a value of $3.2 Billion by 2027. Researchers globally are realising the potential of in vitro applications for drug discovery\, predictivity and validation\, safety\, and toxicity. \n \nSMi’s 5th Annual 3D Cell Culture Conference will be covering the application of 3D cell culture to drug development\, toxicity testing\, and safety assurance. In addition\, the conference will look into the newest breakthroughs in Organ Chip technology\, 3D Multicellular scaffolding\, Microphysiological Systems\, and 3D Bioprinting. In recent years technological advances have made these technologies viable and accessible in scientific application. \nEvent Hashtag: #SMi3DCellCulture \nHIGHLIGHTS FOR 2021 \n\nDiscover the cutting-edge technology that is changing the face of pharmaceutical drug development\nExplore the necessity of utilising 3D models in the cytotoxic testing of biologics over traditional alternatives\nInsight into the capacity for microphysiological systems and organ-on-a-chip technology to mimic cellular microenvironments in vitro\nDiscuss current case studies in applied 3D cell models that are changing the future of pharmaceutical drug discovery\nAssess the biophysiological competency of MPS and 3D Bioprinting at the pre-conference workshops\n\nFEATURED SPEAKERS INCLUDE: \n\nSuzanne Fitzpatrick\, Senior Advisor for Toxicology\, US Food and Drug Administration\nPelin Candarlioglu\, Investigator – Bioengineer/Cell Biologist\, GSK\nRobert Vries\, CEO\, Hubrecht organoid Technology\nSakshi Garg\, Lab Head\, Discovery & Development Technologies\, Merck Group\nRhiannon David\, Scientific Lead Microphysiological Systems\, AstraZeneca\nStephen J. fey\, Founder and Chief Research Officer\, CelVivo\nAlejandro Amador\, Director\, Cellular Assays and Technologies\, Incyte\nFreddy Van Goethem\, Scientific Director – Fellow\, Predictive\, Investigative\, and Translational Toxicology\, Johnson & Johnson; Janssen Pharmaceutical\nJulian Bahr\, Postdoctoral Fellow\, Oncology\, AstraZeneca\nPedro Pinto\, Laboratory Manager\, Urology\, university of Greifswald – Medical Centre\n\nView the full agenda: www.3D-cellculture.com/PJwl \nWHO SHOULD ATTEND? \nBiotech / Pharma Companies – Team Leader\, Junior Principle investigator\, Cell and Molecular Scientist\, Chief Scientific Officer\, Deputy Director\, Manager\, Founder\, CEO\, Head\, Director\, Programme Manager\, Lab Head\, Toxicologist Academia Professor – Cell Technology\, Stem Cell Sciences\, Biochemistry\, Protein Technology and Tissue Engineering Solution Providers – Manager\, Head of\, CEO\, Director\, Founder\, Account Manager\, President\, CSO\, Executive\, Managing Director\, Vice President\, COO \nOrganisations / Regulatory – Director\, Senior Science Advisor\, Scientific Officer
URL:https://www.pharmajournalist.com/event/smis-5th-annual-3d-cell-culture-conference/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210210
DTEND;VALUE=DATE:20210213
DTSTAMP:20260515T145950
CREATED:20201109T113504Z
LAST-MODIFIED:20201109T113504Z
UID:27864-1612915200-1613174399@www.pharmajournalist.com
SUMMARY:5th Annual Liquid Biopsies for Precision Oncology Summit
DESCRIPTION:Welcome to the Digital 5th Liquid Biopsy for Precision Oncology Summit! \nWith two exciting LBx approvals in 2020 and investment pouring into the industry\, these assays are primed to transform the cancer-care space. To realize these untapped opportunities\, it is essential significant sensitivity\, selectivity and analytical roadblocks are addressed to prove utility in the clinic. \n \nThe 5th Annual Liquid Biopsy for Precision Oncology Summit is a crucial date in the industry calendar\, bringing together the entire value chain of oncology drug development to hear and collaborate around the latest advancements innovating cancer detection\, diagnosis and monitoring. \nThis completely online meeting will allow you to discover how latest technologies are being applied to accurately detect and analyze circulating biomarkers earlier\, effectively monitor treatment response and selectively stratify patient populations to enable delivery of targeted therapies in a time-efficient manner. \nFrom biomarker validation through to reimbursement and regulatory\, join your drug development peers striving to translate the clinical applications of liquid biopsies into a worldwide patient reality. \nTo know more about 5th Annual Liquid Biopsies for Precision Oncology Summit please click here.
URL:https://www.pharmajournalist.com/event/5th-annual-liquid-biopsies-for-precision-oncology-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210216
DTEND;VALUE=DATE:20210219
DTSTAMP:20260515T145950
CREATED:20201020T125856Z
LAST-MODIFIED:20201020T130956Z
UID:27553-1613433600-1613692799@www.pharmajournalist.com
SUMMARY:CAR-TCR Summit Europe 2021
DESCRIPTION:Accelerate the Bench to Bedside Development of Novel CAR Immunotherapies for Safe\, Effective & Affordable Advanced Therapies \n \nThe CAR-TCR Digital Summit Europe is the definitive platform for the European community to advance novel cell constructs\, breach the solid tumor microenvironment\, and deliver affordable CAR and TCR technologies to patients in need. \nProviding you with the most comprehensive program this side of the Atlantic\, this summit brings you exclusive insights from the innovators breaking the glass ceiling in T cell engineering\, manufacturing\, safety management and patient accessibility. \nTo know more about CAR-TCR Summit Europe 2021 please click here.
URL:https://www.pharmajournalist.com/event/car-tcr-summit-europe-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T145950
CREATED:20201021T150805Z
LAST-MODIFIED:20201021T150805Z
UID:27572-1613952000-1614297599@www.pharmajournalist.com
SUMMARY:Gene Therapy for Rare Disorders USA
DESCRIPTION:The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market. \nWith investment at an all-time high\, and several indications in late-stage trials gearing up for approval\, the meeting will leverage the experience from first to market pioneers\, as well as unveiling the strategies drug developers are employing to improve efficacy\, safety and commercial viability. \n \nIncorporating insights from 90+ industry-leading speakers\, this digital conference will delve into the key regulatory\, reimbursement\, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies. \nJoin 500+ of your colleagues online to accelerate the progress of the next generation of gene therapies. \nThis is your comprehensive guide to define your commercial path forward.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-rare-disorders-usa/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210225
DTSTAMP:20260515T145950
CREATED:20201111T111102Z
LAST-MODIFIED:20201111T111102Z
UID:27878-1613952000-1614211199@www.pharmajournalist.com
SUMMARY:Operationalize: Expanded Access Programs
DESCRIPTION:Overcome the Operational Hurdles Preventing You From Bringing Treatments to Patients in Need: Say Goodbye to the Worry and Uncertainty of Setting Up and Managing an Expanded Access Program. \n \nBy bringing together the world’s leading thinkers in Expanded Access Programs\, this exclusive platform will clarify the complex issues through end-to-end Expanded Access Program Operationalization. Through open discussion\, sharing best-practice case studies\, and removing hypotheticals: this event provides an unrivalled opportunity to solve your challenges across the entire program timeline. \nOver the course of 3 interactive days\, 20 expert speakers will share their insights on program set-up\, US and EU regulatory pathways\, product supply\, data collection\, using technology to streamline processes and patient communication\, closing out programs and moving to commercialization. So\, next February\, join your peers from across the value chain to develop your own toolkit of solutions from the only case study led\, operationally–focused access programs event. \nTo know more about Operationalize: Expanded Access Programs please click here.
URL:https://www.pharmajournalist.com/event/operationalize-expanded-access-programs/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:nfo@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210224
DTSTAMP:20260515T145950
CREATED:20210114T085910Z
LAST-MODIFIED:20210122T141443Z
UID:28470-1613952000-1614124799@www.pharmajournalist.com
SUMMARY:Animal Health Innovation Europe
DESCRIPTION:The 6th Annual Animal Health Innovation Europe taking place on the 22-23rd February 2021 will showcase the most exciting innovations in animal health and nutrition\, connecting those businesses with financial investors and strategic corporate partners\, making it the sector’s premier investment forum in Europe. \n \nJoin us to hear investment pitches\, network with C-Suite Executives and learn from CEO-level panel discussions that address the trends and market dynamics of the animal health industry\, across all species. This year’s virtual format gives us a unique opportunity with our programming to involve a wider array of stakeholders and key participants in the value chain so we can address the full scope of how animal health impacts pet owners\, veterinarians\, and farmers today. We have advanced our networking capabilities to help you recreate the unexpected business interactions that are so valuable at our face-to-face events\, through virtual roundtable discussions\, workshop groups and interactive content delivery. \nFeaturing speakers from industry leaders such as Elanco\, Zoetis\, Phibro\, and many more\, 2021 content will cover expanded insights on: sustainability and efficiency in the protein supply chain\, the accelerated use of digital solutions in the pet sector\, how the animal health industry will continue to generate value through the Covid-19 pandemic\, and new approaches to stimulate technology adoption and enhance the productivity of European farmers. \nJoin us for the innovation showcase\, a feature of the event that is a unique opportunity for emerging companies with amazing technology to present in front of the industry’s most influential figures and investors. Split between companion and production animal sectors\, 20 start-ups\, hand-picked by the Selection Committee (who all have an extensive breadth of experience and knowledge across animal health and nutrition industries)\, introduce themselves and their innovations and achievements on the main stage. \nBook now to join us in shaping the future of animal health.
URL:https://www.pharmajournalist.com/event/animal-health-innovation-europe/
LOCATION:Virtual
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210224
DTSTAMP:20260515T145950
CREATED:20200525T084418Z
LAST-MODIFIED:20201123T135747Z
UID:25675-1614038400-1614124799@www.pharmajournalist.com
SUMMARY:Purify'20
DESCRIPTION:PURIFY – Chromatography Purification Conclave \nPURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \n \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nThe maiden PURIFY’19 edition was a huge hit amongst fellow chromatographers\, steered by our esteemed advisory board. (For more details please visit: https://www.linkedin.com/showcase/purifyconclave/) PURIFY’19 was attended by 113 delegates across 19 cities\, spread across 51 corporates with 14 speakers and 6 display zones! \nThe knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related. \nLooking forward to seeing you at PURIFY’20!\nV: ITC Kohenur\, Hyderabad\nD: 23 February\, 2021\nTo book your seats please call Rashi: +91-91366 00573
URL:https://www.pharmajournalist.com/event/purify20/
LOCATION:ITC Kohenur\, Hyderabad\, India
ORGANIZER;CN="Custage Marketing Solutions LLP":MAILTO:rashi@custage.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T145950
CREATED:20201109T080924Z
LAST-MODIFIED:20201109T081324Z
UID:27836-1614038400-1614297599@www.pharmajournalist.com
SUMMARY:RAS – Targeted Drug Discovery – Digital Summit
DESCRIPTION:Recent clinical advancements of KRAS G12C inhibitors have generated increased interest in the fight to bring an end to RAS driven cancers. However\, their specificity to only target G12C mutations\, leaves huge untapped therapeutic potential to target all RAS driven cancers beyond the lungs. This calls for continued research efforts by industry and academic experts alike. \n \nThe Digital RAS- Targeted Drug Discovery Summit is the premium forum for cellular\, preclinical and translational RAS experts to explore potential strategies to tackle undrugged RAS oncogenes beyond KRAS G12C. \nAs part of our industry leading and dedicated RAS conference series\, this exciting next iteration is shining the spotlight on: \n§     Identifying key learnings from known pre-clinical and clinical data for viable KRAS direct inhibitors to effectively drug all RAS isoforms \n§     Exploring G12C pre-clinical and clinical data to optimise future RAS targeting strategies \n§     Learning from the patterns of RAS mutations to understand prognostic or predictive power in various cancer types beyond lung cancer \nJoin senior experts from leading biotech\, large pharma and pioneering academic institutions at the Digital RAS- Targeted Drug Discovery Summit as they identify future models and strategies for streamlining anti-RAS therapeutics into the clinic. \nTo know more about RAS – Targeted Drug Discovery please click here.
URL:https://www.pharmajournalist.com/event/ras-targeted-drug-discovery-digital-summit/
LOCATION:Digital Event\, GMT
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T145950
CREATED:20201111T111739Z
LAST-MODIFIED:20201111T111739Z
UID:27882-1614038400-1614297599@www.pharmajournalist.com
SUMMARY:9th Neurodegenerative Drug Development Summit
DESCRIPTION:The 9th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative diseases and combating translational challenges by shining a light on pioneering companies leading the way to meet this dire medical need. \n \nBuilding on the success of last year’s meeting\, this year’s program showcases new biotechs trailblazing this space and will put the spotlight on the latest scientific advances in terms of diverse targets\, novel modalities and innovative trial design. Across 3 action-packed\, case-study driven days and 2 parallel tracks of learning\, we present the opportunity to join us online in 2021 to overcome technical and operational challenges preventing you and your team from translating promising preclinical research into evidenced clinical benefit. \nWhether you are working in a team dedicated to Parkinson’s\, Alzheimer’s\, ALS\, Frontotemporal Dementia or a rare neurodegenerative disorder\, join this intimate\, industry-led forum to not only to learn from those spearheading this space\, but to network and build meaningful partnerships with over 180 neurodegenerative drug development experts. \nTo know more about 9th Neurodegenerative Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/9th-neurodegenerative-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR